SpringLeaf CHITOSAN MAX 3 IN 1 (previously Spring Leaf Fat Clear) (Homart Pharmaceuticals Pty Ltd)
Product Name
SpringLeaf CHITOSAN MAX 3 IN 1 (previously Spring Leaf Fat Clear)
Sponsor
ARTG details
Date of review outcome
Date of publication
Mar-2026
Outcome
Medicine continues to be permitted for supply. Batches released from March 2026 must carry a corrected label.
Is it safe to continue using this medicine?
Yes, based on the sponsor's certification. However, follow the recommended actions below.
What action should consumers take?
This medicine contains phenylalanine. Consider whether this medicine is right for you if you have allergies or sensitivities to this substance. If you develop a reaction, discontinue use and consult a suitably qualified health professional.
Do not exceed a maximum of 3 capsules per day.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to weight management, clearing fat, weight and fat loss, reducing fat and cholesterol absorption, helping to pass out ingested fat and supporting healthy digestive function.
Do not exceed a maximum of 3 capsules per day.
Consider whether this medicine is right for you based on it potentially not working as expected in relation to weight management, clearing fat, weight and fat loss, reducing fat and cholesterol absorption, helping to pass out ingested fat and supporting healthy digestive function.
Review scope
Targeted
Information reviewed
ARTG Record, Labels, Website
Issues related to safety
This medicine contains phenylalanine which was not declared on the label. Phenylalanine is required to be declared on the labels of medicines as it may cause adverse reactions in individuals sensitive to such substances.
This medicine contains an amount of the ingredient Poliglusam that exceeds the permitted limit for listed medicines if taken at the maximum recommended daily dose of 12 capsules stated in the ARTG Record. Ingredient limits for listed medicines are in place to ensure their safety.
The directions for use on the websites and labels for this medicine were inconsistent in both number of capsules required and frequency of dosing. Conflicting directions may lead to unsafe use of listed medicines.
The affected batches of this medicine were recalled and the information on the labels and websites was corrected. As such, this medicine is unlikely to pose a further risk to consumer health and safety.
This medicine contains an amount of the ingredient Poliglusam that exceeds the permitted limit for listed medicines if taken at the maximum recommended daily dose of 12 capsules stated in the ARTG Record. Ingredient limits for listed medicines are in place to ensure their safety.
The directions for use on the websites and labels for this medicine were inconsistent in both number of capsules required and frequency of dosing. Conflicting directions may lead to unsafe use of listed medicines.
The affected batches of this medicine were recalled and the information on the labels and websites was corrected. As such, this medicine is unlikely to pose a further risk to consumer health and safety.
Issues related to efficacy
The name, labels and websites for this medicine contained claims specified in 'What action should consumers take?' above. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor updated the ARTG record, labels and website to correct the issues with this medicine, and the affected batches were recalled.